Top news of the week: 28.10.2021.
Career And Jobs
Catalent's Momentum Continues with Up to 600 New Jobs Being Added
Earlier this month, Catalent announced plans to add 500–600 jobs in Bloomington, Ind., one of its Moderna and Johnson & Johnson COVID-19 vaccine manufacturing sites.
Clinical Catch-Up: October 18-22
It was yet another busy week for clinical trial news. Here’s a look.
BioSpace Movers & Shakers, Oct. 22
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Cambrian secures $100M series C for Roivant-like approach to biotech creation with goal to slow down human aging
Cambrian Biopharma will use $100 million in new financing to bankroll at least three clinical trials within the next 18 months. The biotech has 14 assets in its pipeline from 12 different ...
A quiet cardio upstart makes some noise, getting $300M from Bain and diving deep into the clinic — with some real money for pipeline deals
The small executive team at Cardurion has been sticking carefully to its goals, in-licensing a lead cardio drug from Astellas in 2018 and making a careful trek into human studies as they ...
Following August meltdown, Zymergen hints at salvage plans — cutting jobs and renegotiating loans
Two months after a spectacular implosion that saw its founding CEO leave his post amid customer reports its only product didn’t work, Zymergen provided the first peek behind the curtain for ...
GSK brings Johns Hopkins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO
GlaxoSmithKline CEO Emma Walmsley is adding another scientist to the company’s board. Early Wednesday — alongside their Q3 update — Walmsley put out word that Harry “Hal” Dietz, a professor ...
Vertex signs another Mammoth-sized CRISPR deal with $650M in biobucks on the line
Vertex Pharmaceuticals continues lining up CRISPR gene editing partners, this time linking arms with Jennifer Doudna-founded Mammoth Biosciences for $41 million upfront and $650 million in ...